A Phase 4 interventional study of imatinib mesylate in GIST and CML, sponsored by Novartis Pharmaceuticals. Completed at 29 sites in 11 countries. Open to participants aged 0 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing imatinib in Gastrointestinal Stromal Tumors — 8 open to participants now, 9 under way, 2 of them phase 3. imatinib · Gastrointestinal Stromal Tumors.
Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 3 in phase 4, and was the 34th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →8 of the 50 studies testing imatinib in Gastrointestinal Stromal Tumors are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Kumquat Biosciences Inc. · Sites in United States
Ages 18+
University of California, San Diego · Sites in United States
Ages 18+
Reema A. Patel · Sites in United States
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 20+
By country, each count listing its studies:
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 0 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 27 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 56 across the 50 interventional studies. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Gastrointestinal Stromal Tumors by Novartis: none open now, none under way, none of them phase 3. Of 26 finished, 14 (54%) have results posted.
Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2013, is one of 5 in phase 4, and was the 23rd registered.
Novartis’s Gastrointestinal Stromal Tumors studies by the year they started, since 2000.
1 of the studies testing imatinib in Gastrointestinal Stromal Tumors that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07406633Kumquat Biosciences Inc.KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, from their registry updates:
Among Novartis’s 27 in Gastrointestinal Stromal Tumors:
This tab as a report to print or save as PDF → With an account.
This Phase IV, open-label, multicenter roll-over study evaluated the long-term safety of imatinib in patients who had completed a previous Novartis-sponsored imatinib study and were considered by the investigator to continue benefiting from treatment.
There was no screening period. After providing informed consent and meeting the eligibility criteria, patients entered the study directly from their parent study. The starting imatinib dose was the same as the dose received in the parent study and could subsequently be adjusted based on the investigator's clinical judgment.
Patient evaluations were recommended every 12 weeks, with a permitted window of plus or minus 1 week. Evaluations could be conducted on site or remotely at the investigator's discretion. At each scheduled evaluation, the investigator confirmed whether the patient continued to derive clinical benefit and could remain on study treatment. Patients returned to the study center every 24 weeks, with a permitted window of plus or minus 1 week, for resupply of study medication, unless otherwise managed according to local practice.
Patients continued treatment until they no longer derived clinical benefit, developed unacceptable toxicity, withdrew consent, did not comply with the protocol, discontinued based on the investigator's judgment, died, or transferred to commercial supply in accordance with applicable country requirements.
Adverse events and serious adverse events were collected throughout the treatment period. After the last dose of study treatment, patients were followed for safety for 30 days. The study ended after all patients had completed their final protocol-required assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Highly effective contraception is defined as either:
In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
If a study patient becomes pregnant or suspects they are pregnant during the study or within 30 days of the final dose of imatinib, the Investigator/Study Doctor needs to be informed immediately and ongoing study treatment with imatinib has to be stopped immediately.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who completed a previous Novartis-sponsored imatinib study, continued to derive clinical benefit from treatment, and entered this roll-over study to receive ongoing imatinib therapy. Treatment continued until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, non-compliance, investigator decision, death, or transition to commercial supply, as applicable.
Drug: imatinib mesylate
Imatinib was administered orally at a total daily dose ranging from 100 to 800 milligrams. The starting dose was the same as the dose received in the parent study and could subsequently be adjusted based on the investigator's clinical judgment. Imatinib was supplied as 100 milligram and 400 milligram tablets and was administered once daily or, for patients receiving 800 milligrams daily, as 400 milligrams twice daily.
Also known as: STI571
Frequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Long-term safety was evaluated by assessing the frequency and severity of adverse events and serious adverse events occurring during the study.
Time frame: From first dose of study treatment through 30 days after the last dose of imatinib (up to approximately 157 months)
Proportion of Participants With Clinical Benefit as Assessed by the Investigator
Clinical benefit was assessed by the investigator at scheduled visits, and the proportion of patients who continued to derive clinical benefit from imatinib treatment was summarized throughout the study. At each assessment, the investigator confirmed whether the patient continued to have clinical benefit and could remain on treatment.
Time frame: Up to approximately 157 months
The study was conducted globally across 11 countries: China, Finland, France, Hong Kong, Romania, Singapore, Switzerland, Thailand, Turkey, United Kingdom, and USA.
| Milestone | Imatinib Mesylate |
|---|---|
| Started | 155 |
| Completed | 25 |
| Not completed | 130 |
| Withdrew: Adverse event | 16 |
| Withdrew: Death | 23 |
| Withdrew: Disease progression | 20 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Physician decision | 27 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Subject/guardian decision | 16 |
| Withdrew: Technical problems | 2 |
| Withdrew: Withdrawal by subject | 20 |
Long-term safety was evaluated by assessing the frequency and severity of adverse events and serious adverse events occurring during the study.
| Participants | Imatinib Mesylate |
|---|---|
| All deaths | 27 |
| On treatment deaths | 19 |
| Adverse Events (AEs) - all grades | 88 |
| Treatment-related Adverse events - all grades | 47 |
| Serious Adverse Events (SAEs) - all grades | 48 |
| AEs leading to discontinuation - all grades | 21 |
| AEs leading to dose adjustment/interruption - all grades | 50 |
Clinical benefit was assessed by the investigator at scheduled visits, and the proportion of patients who continued to derive clinical benefit from imatinib treatment was summarized throughout the study. At each assessment, the investigator confirmed whether the patient continued to have clinical benefit and could remain on treatment.
| Participants | Imatinib Mesylate |
|---|---|
| Week 24 | 7 |
| Week 48 | 49 |
| Week 72 | 8 |
| Week 96 | 41 |
| Year 3 | 77 |
| Year 4 | 74 |
| Year 5 | 66 |
| Year 6 | 63 |
| Year 7 | 56 |
| Year 8 | 50 |
| Year 9 | 47 |
| Year 10 | 42 |
| Year 11 | 35 |
| Year 12 | 22 |
| Year 13 | 18 |
Collected over Adverse events were collected from the first dose of study treatment through 30 days after the last dose of imatinib (up to approximately 157 months). The median treatment exposure was 1,485 days (approximately 49 months). Deaths were collected from study entry through study completion (up to approximately 157 months). On-treatment deaths (up to 30 days after last dose) and deaths (thereafter) are reported separately.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imatinib Mesylate (On-Treatment) | 19/155 (12.3%) | 58/155 (37.4%) | 53/155 (34.2%) |
| Imatinib Mesylate (Post-Treatment) | 8/136 (5.9%) | — | — |
| Event | Imatinib Mesylate (On-Treatment) | Imatinib Mesylate (Post-Treatment) |
|---|---|---|
| PneumoniaInfections and infestations | 13/155 | — |
| Hip fractureInjury, poisoning and procedural complications | 6/155 | — |
| AnaemiaBlood and lymphatic system disorders | 4/155 | — |
| Cardiac failure congestiveCardiac disorders | 4/155 | — |
| Urinary tract infectionInfections and infestations | 4/155 | — |
| Second primary malignancyNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/155 | — |
| Atrial fibrillationCardiac disorders | 3/155 | — |
| Myocardial infarctionCardiac disorders | 3/155 | — |
| Gastrointestinal haemorrhageGastrointestinal disorders | 3/155 | — |
| DeathGeneral disorders | 3/155 | — |
| Event | Imatinib Mesylate (On-Treatment) | Imatinib Mesylate (Post-Treatment) |
|---|---|---|
| Blood creatinine increasedInvestigations | 17/155 | — |
| NauseaGastrointestinal disorders | 12/155 | — |
| AnaemiaBlood and lymphatic system disorders | 11/155 | — |
| DiarrhoeaGastrointestinal disorders | 11/155 | — |
| Back painMusculoskeletal and connective tissue disorders | 11/155 | — |
| MyalgiaMusculoskeletal and connective tissue disorders | 10/155 | — |
| COVID-19Infections and infestations | 9/155 | — |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/155 | — |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 9/155 | — |
| Periorbital oedemaEye disorders | 8/155 | — |
| Age, Continuous(Years) | Imatinib Mesylate |
|---|---|
| Mean | 64.3 ± 13.07 |
| Sex: Female, Male(Participants) | Imatinib Mesylate |
|---|---|
| Female | 63 |
| Male | 92 |
| Race and Ethnicity Not Collected(Participants) | Imatinib Mesylate |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2013 to primary completion in Apr 2026, 156 months.
Results were first posted in Oct 2026, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Gastrointestinal Stromal Tumors →